Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PanCAN 2nd annual Therapeutic Accelerator Award Goes to ONCY

<< Previous

Bullboard Posts

Next >>

Comment by pelabooston Oct 10, 2023 1:49pm

121 Views

Post# 35677371

RE:RE:PanCAN 2nd annual Therapeutic Accelerator Award Goes to ONCY

@Notebook. In the 9/26 release it was stated - pela plus modified Folfirinox with or without a CPI. Implying 2 combos? I would doubt that has changed, unless a decision has been take for CPI plus pela plus Folfirinox solely. Does the modified Folfirinox get only a CPI and pela or are they going with and without. A key piece of knowledge.

TIA

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024